Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Unpacking Data From Pivotal Trials in Multiple Myeloma: Lessons Learned From the MajesTEC-1 Trial of Teclistamab

January 25th 2023

In this third episode of OncChats: Unpacking Data From Pivotal Trials in Multiple Myeloma, Hamza Hashmi, MD, highlights the efficacy and safety profile of teclistamab, a BCMA-directed bispecific T-cell engager, in heavily pretreated multiple myeloma.

Dr. Giralt on Long-Term Outcomes with HSCT in Multiple Myeloma

January 25th 2023

Sergio A. Giralt, MD, discusses long-term outcomes with hematopoietic stem cell transplant in multiple myeloma

Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma Patients With High-Risk Cytogenetics: IKEMA Subgroup Analysis

January 25th 2023

Expert hematologist-oncologist Thomas G. Martin, MD, shares data from the IKEMA subgroup analysis in patients with relapsed multiple myeloma treated with isatuximab, carfilzomib, and dexamethasone.

Ide-cel Elicits Durable Responses in High-risk Myeloma After Inadequate ASCT Response

January 24th 2023

David Siegel, MD, PhD, discusses the evaluation of idecabtagene vicleucel in cohort 2C of the KarMMa-2 trial and what these data could mean for this population and others with multiple myeloma.

Approaches to Treatment Duration in Newly-Diagnosed Multiple Myeloma

January 23rd 2023

Noopur Raje, MD, details the data on treatment duration in older patients with multiple myeloma and transplant-eligible patients.

Defining Frailty in Multiple Myeloma for Optimal Treatment

January 23rd 2023

Amrita Krishnan, MD, and Hana Safah, MD, discuss how to measure frailty in patient with multiple myeloma.

Dr. Chari on Avenues for Future Research in Newly Diagnosed Multiple Myeloma

January 20th 2023

Ajay Chari, MD, discusses several avenues for future study in newly diagnosed multiple myeloma.

Unpacking Data From Pivotal Trials in Multiple Myeloma: Shining a Light on the MASTER Trial Evaluating D-KRd

January 18th 2023

In this second episode of OncChats: Unpacking Data From Pivotal Trials in Multiple Myeloma, Hamza Hashmi, MD, discusses the depth of response reported with daratumumab, carfilzomib, lenalidomide, and dexamethasone in transplant-eligible multiple myeloma.

Unmet Needs in the Treatment of NDMM and R/R MM and Clinical Pearls for Community Oncologists

January 17th 2023

The panel closes their discussion by highlighting unmet needs in the multiple myeloma treatment landscape and sharing advice for physicians and patients.

Treatment Options for MM at Early Relapse

January 17th 2023

Krina Patel, MD, explains the treatment options for patients with early relapsed multiple myeloma.

Daratumumab, Lenalidomide, Dexamethasone Improves OS in Relapsed/Refractory Multiple Myeloma

January 16th 2023

The addition of daratumumab to lenalidomide and dexamethasone led to a 27% reduction in the risk of death compared with Rd alone in patients with relapsed/refractory multiple myeloma.

Unpacking Data From Pivotal Trials in Multiple Myeloma: Examining Findings From the GRIFFIN Trial of D-RVd

January 13th 2023

In this first episode of OncChats: Unpacking Data From Pivotal Trials in Multiple Myeloma, Hamza Hashmi, MD, provides perspective on the use of daratumumab-based quadruplets as induction therapy in multiple myeloma.

Teclistamab Plus Daratumumab/Lenalidomide Generates Responses in Relapsed/Refractory Myeloma

January 13th 2023

Emma Searle, PhD, provides an overview of findings from the MajesTEC-2 trial in patients with relapsed/refractory multiple myeloma, elaborates on the safety of teclistamab plus daratumumab and lenalidomide, and discusses the next steps for evaluating the combination.

Final Thoughts on Case Study and Treating Multiple Myeloma

January 12th 2023

Dr Joseph Mikhael and expert panel re-visit the patient case and offer their final thoughts on the impact of clinical trial updates in the treatment landscape of multiple myeloma.

Chari Spotlights Efficacy of Talquetamab and Next Steps for Exploration in R/R Multiple Myeloma

January 12th 2023

Ajai Chari, MD, shares some background on talquetamab, reported safety and efficacy findings from MonumenTAL-1, and highlighted other ways in which the agent is being explored in multiple myeloma.

Clinical Trials in R/R Multiple Myeloma

January 12th 2023

Dr Joseph Mikhael and expert panel discuss key efficacy and safety outcomes of pivotal clinical trials evaluating treatment regimens in patients with R/R multiple myeloma.

Key Considerations for Patients with Multiple Myeloma During the Treatment Journey

January 10th 2023

Jenny Ahlstrom, a patient with multiple myeloma, shares considerations for patients going through treatment, including toxicities, follow-up, and travel planning.

Available Induction Treatment Regimens for Patients with Transplant-Ineligible MM

January 10th 2023

Shaji Kumar, MD, and Krina Patel, MD, discuss the treatment options for patients with newly-diagnosed multiple myeloma who are not eligible for stem cell transplant.

Treatment Options in Early Relapse Multiple Myeloma

January 5th 2023

Dr Joseph Mikhael and expert panel review current treatment options for patients with early relapse multiple myeloma, in accordance with current NCCN guidelines.

Case Study: Myeloma at Early Relapse

January 5th 2023

Dr Joseph Mikhael and expert panel review a case study in early relapse multiple myeloma and the impact of cytogenetics in risk assessment for patients with early relapse multiple myeloma.